Advances in Cancer Immunotherapy™: A Focus on Cell Therapies and T cell Engagers

When:  Aug 17, 2023 from 12:00 to 16:00 (ET)

This program will be hybrid. Please attend in-person or virtually!


Lekha Mikkilineni, MD - Stanford University
Nirali N. Shah, MD, MHSc - National Cancer Institute, National Institutes of Health
Bonnie Yates, MSN, CPNP-AC - National Institutes of Health

Program Purpose

Specifically designed by the Society for Immunotherapy of Cancer (SITC) for practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals, the Advances in Cancer Immunotherapy™ (ACI) programs are introductory, CME-, CPE-, CNE-, MOC-certified programs. Presented by leading authorities in tumor immunology and cancer immunotherapy, at the conclusion of this activity, participants of this should be able to:

  • Describe the mechanisms of cell therapies and T cell engagers.
  • Summarize recent updates in the use of cell therapies and T cell engagers clinically.
  • Outline common toxicities with cell therapies and T cell engagers and their management.
  • Identify unique institutional resources required for the appropriate use of cell therapies.
Attendees will also have an opportunity for connecting with experts in the immunotherapy field at the live event, through four quarterly webinars, and indefinitely through a dedicated online community forum. These connections will serve as ongoing resources while clinical oncologists and other healthcare providers incorporate immunotherapy into practice.

For more information on the program, click below.


View the SITC Meeting Code of Conduct.


The Westin Washington, D.C. City Center
1400 M St NW
Washington DC, DC 20005